ginsenoside rh2 has been researched along with ritonavir in 1 studies
Studies (ginsenoside rh2) | Trials (ginsenoside rh2) | Recent Studies (post-2010) (ginsenoside rh2) | Studies (ritonavir) | Trials (ritonavir) | Recent Studies (post-2010) (ritonavir) |
---|---|---|---|---|---|
295 | 1 | 200 | 5,419 | 1,291 | 2,772 |
Protein | Taxonomy | ginsenoside rh2 (IC50) | ritonavir (IC50) |
---|---|---|---|
Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | 6.1 | |
Bile salt export pump | Homo sapiens (human) | 2.085 | |
ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.65 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.1623 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 2.3 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 2.458 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.067 | |
Substance-K receptor | Homo sapiens (human) | 2.622 | |
UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 2.35 | |
Thromboxane-A synthase | Homo sapiens (human) | 0.076 | |
Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 4.4 | |
Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.1933 | |
Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.4 | |
Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 2 | |
Protease | Human immunodeficiency virus 1 | 4.9253 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aa, JY; Cao, B; Ge, C; Gu, RR; Li, MJ; Liu, CX; Liu, LS; Ma, T; Mao, Y; Shi, J; Sun, RB; Wang, GJ; Wang, XW; Wu, XL; Xia, WJ; Xiao, WJ; Yu, XY; Zha, WB; Zheng, T; Zhou, J | 1 |
1 other study(ies) available for ginsenoside rh2 and ritonavir
Article | Year |
---|---|
Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo.
Topics: Acridines; Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Chromatography, Liquid; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Ginsenosides; HIV Protease Inhibitors; Humans; Injections, Intravenous; Madin Darby Canine Kidney Cells; Male; Mass Spectrometry; Rats; Rats, Wistar; Ritonavir; Tetrahydroisoquinolines; Tissue Distribution; Verapamil | 2013 |